Cargando…
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
Visceral leishmaniasis is a neglected tropical disease endemic in East Africa where improved patient-adapted treatments are needed. The Leishmaniasis East Africa Platform (LEAP) was created in 2003 to strengthen clinical research capacity, serve as a base for training, and evaluate and facilitate im...
Autores principales: | Wasunna, Monique, Musa, Ahmed, Hailu, Asrat, Khalil, Eltahir A. G., Olobo, Joseph, Juma, Rashid, Wells, Susan, Alvar, Jorge, Balasegaram, Manica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926319/ https://www.ncbi.nlm.nih.gov/pubmed/27268714 http://dx.doi.org/10.1093/trstmh/trw031 |
Ejemplares similares
-
Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011) -
Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005) -
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010) -
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017) -
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)